Clarity

Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Retrieved on: 
Monday, April 1, 2024

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).

Key Points: 
  • LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).
  • Eisai had aimed to submit a Biologics License Application (BLA) for weekly maintenance therapy using subcutaneous (SC) administration in March 2024.
  • However, Eisai was recently informed by the FDA that a Fast Track designation specific for the SC formulation is needed to receive rolling review.
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Clarity Technologies Announces Significant Enhancements and Strategic Integrations to The Clarity Practice Performance System

Retrieved on: 
Thursday, May 9, 2024

BOISE, Idaho, May 9, 2024 /PRNewswire/ -- Clarity Technologies, which recently revealed its rebrand following the merger of Engage Technologies Group and APX Platform, announces substantial new product features and strategic integrations for the Clarity Practice Performance System.

Key Points: 
  • BOISE, Idaho, May 9, 2024 /PRNewswire/ -- Clarity Technologies, which recently revealed its rebrand following the merger of Engage Technologies Group and APX Platform, announces substantial new product features and strategic integrations for the Clarity Practice Performance System.
  • The Clarity Practice Performance System is a first-of-its-kind healthcare practice software designed to give practice managers and owners a holistic way to optimize practice operations.
  • Finally, Clarity is announcing strategic integrations with robust EHRs like ModMed and Symplast, as well as the practice management software; Promptly.
  • Additionally, the integration with Symplast allows for seamless access to the Clarity Practice Performance System analytics module that provides structured data, industry benchmarks, and actionable insights for aesthetic practices.

Nepsis® Appoints Amanda Butler as its First Chief Technology Officer

Retrieved on: 
Tuesday, May 7, 2024

(“Nepsis®”), a national financial advisor and investment management firm, today announced Amanda Butler has joined the firm as its first chief technology officer (CTO).

Key Points: 
  • (“Nepsis®”), a national financial advisor and investment management firm, today announced Amanda Butler has joined the firm as its first chief technology officer (CTO).
  • In joining Nepsis®, Butler will focus on enhancing and growing the firm’s technology stack to further integrate its wealth management and tax services business lines and ensure it stays ahead of the technology curve.
  • In her new role, Butler will lead Nepsis®’ technology vision and strategy as well as oversee the firm’s technical infrastructure.
  • Further, she will manage technology vendor partnerships and collaborate with the design team on product development to introduce new Nepsis® offerings to the market.

Engage Technologies Group and APX Platform Unveil Bold Rebrand as Clarity Technologies

Retrieved on: 
Wednesday, May 1, 2024

BOISE, Idaho, May 1, 2024 /PRNewswire/ -- Engage Technologies and APX Platform have revealed their new brand identity as Clarity Technologies. In uniting these two companies and combining their product offerings into one unique platform, the rebranding initiative underscores a commitment to improve healthcare operations, placing their product, the Practice Performance System, as the ultimate compliment to Electronic Medical Record and Practice Management Systems.

Key Points: 
  • BOISE, Idaho, May 1, 2024 /PRNewswire/ -- Engage Technologies and APX Platform have revealed their new brand identity as Clarity Technologies.
  • Clarity Technologies is the creator of the Practice Performance System, a new category of practice software.
  • When Engage Technologies Group and APX Platform merged in early 2023, it paved the way for this brand.
  • Inspired by the transformative power of clarity, Clarity Technologies is poised to help navigate healthcare practices through the complexities of achieving profitability and efficiency.

C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market

Retrieved on: 
Friday, April 26, 2024

Hoshiko, who’s based in Kyoto, Japan, has a well-established background as a neuroscientist focused on the commercialization aspects of the field.

Key Points: 
  • Hoshiko, who’s based in Kyoto, Japan, has a well-established background as a neuroscientist focused on the commercialization aspects of the field.
  • Other research has found that Japan has the highest proportion of people with dementia of any country.
  • We believe our partnership with Mediford Corporation will unlock many opportunities and possibilities.
  • Mediford Corporation is known for providing clinical and non-clinical analysis that supports each stage of drug research and development, including advanced treatment options.

Perceptyx Announces Winners of 2024 EX IMPACT Awards

Retrieved on: 
Thursday, April 4, 2024

TEMECULA, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, today announced the winners of its inaugural EX IMPACT Awards, which honor the ways companies discovered insights, acted on results, and impacted their employees’ experience using Perceptyx’s People Insights Platform.

Key Points: 
  • TEMECULA, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, today announced the winners of its inaugural EX IMPACT Awards, which honor the ways companies discovered insights, acted on results, and impacted their employees’ experience using Perceptyx’s People Insights Platform.
  • The EX IMPACT Awards recognize people-first organizations making a difference in workplace culture.
  • “The EX IMPACT Awards recognize organizations that use the Perceptyx People Insights Platform to improve their employees’ experience,” said Kirsten Helvey, Chief Customer Officer at Perceptyx.
  • “This EX Impact Award showcases the potential this type of strategy carries not only for our organization but others as well!”

Without the use of third-party auditors in carbon reporting, companies report lower, but unreliable, emissions

Retrieved on: 
Tuesday, March 26, 2024

Companies that do engage third-party auditors, while they may show higher current emissions, take actionable steps to reduce their future carbon emissions.

Key Points: 
  • Companies that do engage third-party auditors, while they may show higher current emissions, take actionable steps to reduce their future carbon emissions.
  • As opposed to those who do not audit their emissions, companies that provide accurate emissions reporting actively set appropriate targets and reduce their future emissions.
  • “It makes sense to also include smaller companies in the scope of companies that need to obtain assurance for their carbon emissions.
  • Without accurately reported data from all companies, working to reduce carbon emissions will forever be an impossible hurdle,” concluded Berg.

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

Retrieved on: 
Monday, March 11, 2024

BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.

Key Points: 
  • BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.
  • Lecanemab was designed to preferentially bind soluble (protofibrils), as well as insoluble Aβ aggregates (fibrils), to reduce both Aβ protofibrils and Aβ plaques in the brain.
  • The difference in binding to CAA[1] was presented, with lecanemab having lower binding to CAA than most other antibodies.
  • This could explain the difference in the adverse event ARIA[2] seen between different antibodies, with lecanemab showing relatively low incidence of ARIA.

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Retrieved on: 
Thursday, February 29, 2024

In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.

Key Points: 
  • In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.
  • At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ antibodies.
  • In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented.
  • Lecanemab for the treatment of early Alzheimer's disease: the extension of efficacy results from Clarity AD